Molecular Weight-Dependent Influence of Heparin on the Form of Tissue Factor Pathway Inhibitor Circulating in Plasma

 

 Buy Article Permissions and Reprints

ABSTRACT

The increase of circulating tissue factor pathway inhibitor (TFPI) in plasma by heparins is thought to contribute to their overall antithrombotic activity. In a clinical study in healthy volunteers, we recently found that the specific potency of a heparin to mobilize TFPI from the vessel wall increases with its molecular weight (MW). The released TFPI originally is not associated with lipoproteins, but it is not known whether it remains free circulating in plasma. A further question is whether the MW of heparin influences not only the release of TFPI but also its potential association with lipoproteins. In the present study, the release of free TFPI was compared with the release of total TFPI after application of four heparins with different MWs. Only the TFPI released by unfractionated heparin (UFH) circulated completely as free TFPI. With decreasing heparin MW, the percentage of released free TFPI on released total TFPI decreased to 57%. As a consequence, the longer the heparin chains are, the better they are at preventing the binding of the released, originally free, TFPI to plasma lipoproteins. Because only free TFPI is known to exhibit anticoagulant activity, the activity of released TFPI is better the higher the MW of the applied heparin is. In conclusion, in addition to the potency of heparin to mobilize TFPI, there is its influence on the circulating form, and thus the anticoagulant activity of the released TFPI depends on its MW.

REFERENCES

• 1 Broze Jr J G. Tissue factor pathway inhibitor and the revised theory of coagulation.  Annu Rev Med . 1995;  46 103-112
  CrossrefPubMedGoogle Scholar
• 2 Sandset P M, Abildgaard U, Larsen M L. Heparin induces release of extrinsic coagulation pathway inhibitor (EPI).  Thromb Res . 1988;  50 803-813
  CrossrefPubMedGoogle Scholar
• 3 Hamamoto T, Kisiel W. The effect of heparin on the regulation of factor VIIa-tissue factor activity by tissue factor pathway inhibitor.  Blood Coagul Fibrinolysis . 1996;  7 470-476
  PubMedGoogle Scholar
• 4 Abildgaard U. Heparin/low molecular weight heparin and tissue factor pathway inhibitor.  Haemostasis . 1993;  23(Suppl 1) 103-106
  PubMedGoogle Scholar
• 5 Hansen J B, Huseby K R, Huseby N E. Effect of cholesterol lowering on intravascular pools of TFPI and its anticoagulant potential in type II hyperlipoproteinemia.  Arterioscler Thromb Vasc Biol . 1995;  15 879-885
  CrossrefPubMedGoogle Scholar
• 6 Lindahl A K, Sandset P M, Abildgaard U. The present status of tissue factor pathway inhibitor.  Blood Coagul Fibrinolysis . 1992;  3 439-449
  PubMedGoogle Scholar
• 7 Hansen J B, Huseby K R, Huseby N E, Ezban M, Nordoy A. Tissue factor pathway inhibitor in complex with low density lipoprotein isolated from human plasma does not possess anticoagulant function in tissue factor-induced coagulation in vitro.  Thromb Res . 1997;  85 413-425
  CrossrefPubMedGoogle Scholar
• 8 Kojima T, Katsumi A, Yamazaki T. Human ryudocan from endothelium-like cells binds basic fibroblast growth factor, midkine, and tissue factor pathway inhibitor.  J Biol Chem . 1996;  271 5914-5920
  CrossrefPubMedGoogle Scholar
• 9 Iversen N, Sandset P M, Abildgaard U, Torjesen P A. Binding of tissue factor pathway inhibitor to cultured endothelial cells-influence of glycosaminoglycans.  Thromb Res . 1996;  84 267-278
  CrossrefPubMedGoogle Scholar
• 10 Wesselschmidt R, Likert K, Huang Z, MacPhail L, Broze Jr J G. Structural requirements for tissue factor pathway inhibitor interactions with factor Xa and heparin.  Blood Coagul Fibrinolysis . 1993;  4 661-669
  CrossrefPubMedGoogle Scholar
• 11 Enjyoji K, Miyata T, Kamikubo Y, Kato H. Effect of heparin on the inhibition of factor Xa by tissue factor pathway inhibitor: a segment, Gly212-Phe243, of the third Kunitz domain is a heparin-binding site.  Biochemistry . 1995;  34 5725-5735
  CrossrefPubMedGoogle Scholar
• 12 Valentin S, Nordfang O, Bregengard C, Wildgoose P. Evidence that the C-terminus of tissue factor pathway inhibitor (TFPI) is essential for its in vitro and in vivo interaction with lipoproteins.  Blood Coagul Fibrinolysis . 1993;  4 713-720
  PubMedGoogle Scholar
• 13 Novotny W F, Palmier M, Wun T C, Broze Jr J G, Miletich J P. Purification and properties of heparin-releasable lipoprotein-associated coagulation inhibitor.  Blood . 1991;  78 394-400
  PubMedGoogle Scholar
• 14 Bridey F, Lacombe C, Sustendal L. Development of a method to separate lipoprotein-bound and lipoprotein-depleted tissue factor pathway inhibitor. Measurement of free tissue factor pathway inhibitor activity.  Blood Coagul Fibrinolysis . 1998;  9 637-643
  PubMedGoogle Scholar
• 15 Alban S, Gastpar R. Plasma levels of total and free tissue factor pathway inhibitor (TFPI) as individual pharmacological parameters of various heparins.  Thromb Haemost . 2001 (in press); 
  PubMedGoogle Scholar
• 16 Witt I, Beeser H, Müller-Berghaus G. Minimalanforderungen zur Gewinnung von Citratplasma für hämostaseologische Analysen.  Lab Med . 1995;  19 143-145
  PubMedGoogle Scholar
• 17 Alban S, Gastpar R. In vitro influence of heparin on plasma total and free tissue factor pathway inhibitor (TFPI) as measured by ELISA.  Pharm Pharmacol Lett . 2000;  10 51-54
  PubMedGoogle Scholar
• 18 Gibaldi M, Perrier D. Pharmacokinetics, 2nd ed. New York: Marcel Dekker; 1992 . 
  Google Scholar
• 19 Rowland M, Tozer T N. Clinical Pharmacokinetics.  Concepts and Applications. Philadelphia: JB Lippincott 1995: 469-472
  Google Scholar
• 20 Zincke R. Generica, Version 2.0 Coesfeld, Germany 1989
  Google Scholar
• 21 Valentin S, Ostergaard P, Kristensen H, Nordfang O. Synergism between full length TFPI and heparin: evidence for TFPI as an important factor for the antithrombotic activity of heparin.  Blood Coagul Fibrinolysis . 1992;  3 221(Lett)-222(Lett)
  PubMedGoogle Scholar
• 22 Wun T C. Lipoprotein-associated coagulation inhibitor (LACI) is a cofactor for heparin: synergistic anticoagulant action between LACI and sulfated polysaccharides.  Blood . 1992;  79 430-438
  PubMedGoogle Scholar
• 23 Albada J, Nieuwnhuis H K, Sixma J J. Pharmacokinetics of standard and low molecular weight heparin. In: Lane DA, Lindahl U, eds. Heparin: Chemical and Biological Properties, Clinical Applications London: Edward Arnold 1989: 417-431
  Google Scholar
• 24 Valentin S, Larnkjer A, Ostergaard P, Nielsen J I, Nordfang O. Characterization of the binding between tissue factor pathway inhibitor and glycosaminoglycans.  Thromb Res . 1994;  75 173-183
  CrossrefPubMedGoogle Scholar
• 25 Sandset P M, Abildgaard U, Larsen M L. Heparin induces release of extrinsic coagulation pathway inhibitor (EPI).  Thromb Res . 1988;  50 803-813
  CrossrefPubMedGoogle Scholar
• 26 Lindahl A K, Jacobsen P B, Sandset P M, Abildgaard U. Tissue factor pathway inhibitor with high anticoagulant activity is increased in post-heparin plasma and in plasma from cancer patients.  Blood Coagul Fibrinolysis . 1991;  2 713-721
  PubMedGoogle Scholar
• 27 Sun L B, Utoh J, Kunitomo R. Altered plasma antigen levels of tissue factor pathway inhibitor during open-heart surgery.  Surg Today . 2000;  30 122-126
  CrossrefPubMedGoogle Scholar
• 28 Falkon L, Garí M, Barbnanoj M, Amiral J, Fontcuberta J. Tissue factor pathway inhibitor and anti-FXa kinetic profiles of a new low-molecular-mass heparin, bemiparin, as therapeutic subcutaneous doses.  Blood Coagul Fibrinolysis . 1998;  9 137-141
  PubMedGoogle Scholar
• 29 Altman R, Scazziota A, Rouvier J. Efficacy of unfractionated heparin, low molecular weight heparin and both combined for releasing total and free tissue factor pathway inhibitor.  Haemostasis . 1998;  28 229-235
  CrossrefPubMedGoogle Scholar
• 30 Bendz B, Hansen J B, Andersen T O, Ostergaard P, Sandset P M. Partial depletion of tissue factor pathway inhibitor during subcutaneous administration of unfractionated heparin, but not with two low molecular weight heparins.  Br J Haematol . 1999;  107 756-762
  CrossrefPubMedGoogle Scholar